MX2020006798A - Derivado de amino-metil piperidina como inhibidor de cinasa. - Google Patents

Derivado de amino-metil piperidina como inhibidor de cinasa.

Info

Publication number
MX2020006798A
MX2020006798A MX2020006798A MX2020006798A MX2020006798A MX 2020006798 A MX2020006798 A MX 2020006798A MX 2020006798 A MX2020006798 A MX 2020006798A MX 2020006798 A MX2020006798 A MX 2020006798A MX 2020006798 A MX2020006798 A MX 2020006798A
Authority
MX
Mexico
Prior art keywords
amino
kinase inhibitor
methyl piperidine
piperidine derivative
present
Prior art date
Application number
MX2020006798A
Other languages
English (en)
Inventor
In Woo Kim
Jun Hee Lee
Nam Youn Kim
Seung Hwarn Jeong
Bo-Kyoung Kim
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MX2020006798A publication Critical patent/MX2020006798A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a un compuesto representado por la siguiente Fórmula Química 1, o a una sal farmacéuticamente aceptable del mismo, y el compuesto de acuerdo con la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades que están asociadas con acciones inhibidoras de cinasas.
MX2020006798A 2017-12-28 2018-12-28 Derivado de amino-metil piperidina como inhibidor de cinasa. MX2020006798A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170183062A KR102577242B1 (ko) 2017-12-28 2017-12-28 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
PCT/KR2018/016813 WO2019132561A1 (ko) 2017-12-28 2018-12-28 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체

Publications (1)

Publication Number Publication Date
MX2020006798A true MX2020006798A (es) 2020-09-03

Family

ID=67067897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006798A MX2020006798A (es) 2017-12-28 2018-12-28 Derivado de amino-metil piperidina como inhibidor de cinasa.

Country Status (23)

Country Link
US (1) US11407754B2 (es)
EP (1) EP3733674B1 (es)
JP (1) JP7024091B2 (es)
KR (1) KR102577242B1 (es)
CN (1) CN111527088B (es)
AU (1) AU2018394996B2 (es)
BR (1) BR112020013237A2 (es)
CA (1) CA3085160C (es)
CL (1) CL2020001749A1 (es)
CO (1) CO2020007156A2 (es)
DO (1) DOP2020000111A (es)
EC (1) ECSP20035588A (es)
ES (1) ES2924225T3 (es)
MA (1) MA51433A (es)
MX (1) MX2020006798A (es)
MY (1) MY196572A (es)
NZ (1) NZ765152A (es)
PE (1) PE20210549A1 (es)
RU (1) RU2756505C1 (es)
SA (1) SA520412334B1 (es)
SG (1) SG11202004916YA (es)
TN (1) TN2020000081A1 (es)
WO (1) WO2019132561A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200036004A (ko) 2017-08-01 2020-04-06 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
RS63515B1 (sr) 2017-12-28 2022-09-30 Daewoong Pharmaceutical Co Ltd Derivat oksi-fluoropiperidina kao inhibitor kinaze
WO2020154350A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
KR102228668B1 (ko) * 2019-10-08 2021-03-17 (주)부흥산업사 메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법
CN112824381B (zh) * 2019-11-21 2024-04-26 广东东阳光药业股份有限公司 一种哌啶胺的制备方法
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
WO2021147952A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN113214265B (zh) * 2020-01-21 2023-07-07 江苏先声药业有限公司 嘧啶并五元环类化合物
CN115244055A (zh) * 2020-01-21 2022-10-25 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
WO2022062601A1 (zh) * 2020-09-22 2022-03-31 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Egfr阻害剤及び疾患の治療方法
CA2803056C (en) 2010-06-23 2017-05-16 Hanmi Science Co., Ltd. Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
AU2012311184A1 (en) * 2011-09-22 2014-03-06 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
ES2618007T3 (es) * 2012-08-06 2017-06-20 Acea Biosciences, Inc. Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas
DK2917138T3 (en) 2012-11-08 2019-04-15 Compac Tech Limited ARTICLE CARRIER FOR A SORTING DEVICE
KR20150108389A (ko) 2013-01-16 2015-09-25 시그날 파마소티칼 엘엘씨 치환된 피롤로피리미딘 화합물, 이의 조성물 및 이에 의한 치료 방법
BR112016005881A2 (pt) 2013-09-18 2017-09-12 Beijing Hanmi Pharmaceutical Co Ltd composto, composição farmacêutica e uso do composto
PT3077395T (pt) 2013-12-05 2018-01-03 Pfizer Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas
CN105732637B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
AU2016369584A1 (en) 2015-12-16 2018-07-19 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
AU2017287762C1 (en) 2016-06-30 2020-04-23 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
CN106432294B (zh) 2016-09-19 2018-01-30 淮北师范大学 发光配合物及其制备方法
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
RS63515B1 (sr) 2017-12-28 2022-09-30 Daewoong Pharmaceutical Co Ltd Derivat oksi-fluoropiperidina kao inhibitor kinaze
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체

Also Published As

Publication number Publication date
CO2020007156A2 (es) 2020-06-19
SG11202004916YA (en) 2020-06-29
CN111527088A (zh) 2020-08-11
WO2019132561A8 (ko) 2020-06-11
DOP2020000111A (es) 2020-09-30
RU2756505C1 (ru) 2021-10-01
CA3085160C (en) 2021-12-07
US11407754B2 (en) 2022-08-09
AU2018394996A1 (en) 2020-06-25
JP2021507923A (ja) 2021-02-25
CA3085160A1 (en) 2019-07-04
ECSP20035588A (es) 2020-07-31
NZ765152A (en) 2024-02-23
AU2018394996A2 (en) 2020-07-16
MY196572A (en) 2023-04-19
BR112020013237A2 (pt) 2020-12-01
KR20190080541A (ko) 2019-07-08
AU2018394996B2 (en) 2021-08-05
JP7024091B2 (ja) 2022-02-22
SA520412334B1 (ar) 2022-11-03
ES2924225T3 (es) 2022-10-05
EP3733674A4 (en) 2021-06-09
MA51433A (fr) 2021-04-07
US20210188854A1 (en) 2021-06-24
WO2019132561A1 (ko) 2019-07-04
EP3733674A1 (en) 2020-11-04
EP3733674B1 (en) 2022-06-29
CN111527088B (zh) 2022-12-30
TN2020000081A1 (en) 2022-01-06
PE20210549A1 (es) 2021-03-17
KR102577242B1 (ko) 2023-09-11
CL2020001749A1 (es) 2020-11-06

Similar Documents

Publication Publication Date Title
NZ765152A (en) Amino-methyl piperidine derivative as kinase inhibitor
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12019500480A1 (en) Pyridine compound
MY197698A (en) Oxysterols and methods of use thereof
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
PH12018500999A1 (en) Sodium channel blocker
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor